ホーム>>Signaling Pathways>> PROTAC>> Ligand for Target Protein for PROTAC>>SLF TFA

SLF TFA

カタログ番号GC61461

SLF TFA は、FK506 結合タンパク質 (FKBP) の合成リガンドであり、FKBP51 に対して 3.1 μM の親和性を持ち、FKBP12 に対して 2.6 μM の IC50 を持ちます。 SLF TFA は PROTAC の合成に使用できます。

Products are for research use only. Not for human use. We do not sell to patients.

SLF TFA 化学構造

Cas No.: 2378802-47-0

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$98.00
在庫あり
5 mg
$70.00
在庫あり
10 mg
$130.00
在庫あり
50 mg
$519.00
在庫あり
100 mg
$862.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SLF TFA is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for FKBP51 and an IC50 of 2.6 μM for FKBP12. SLF TFA can be used in the synthesis of PROTAC[1][2][3].

Three scout fragments-KB02, KB03, and KB05 are fused, which cover two different electrophile groups (chloroacetamide and acrylamide) and display broad cysteine reactivity in the human proteome-to the SLF ligand that binds tightly and selectively to FKBP12, a cytosolic prolyl isomerase that has been frequently used to study ligand-induced protein degradation[3].

[1]. Kolos JM, et al. FKBP Ligands-Where We Are and Where to Go• Front Pharmacol. 2018 Dec 5;9:1425. [2]. Wu X, et al. Creating diverse target-binding surfaces on FKBP12: synthesis and evaluation of a rapamycin analogue library. ACS Comb Sci. 2011 Sep 12;13(5):486-95. [3]. Zhang X, et al. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. Nat Chem Biol. 2019 Jul;15(7):737-746.

レビュー

Review for SLF TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SLF TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.